Advertisement

Advertisement
Solid Tumors
Hematologic Malignancies
Immunotherapy

Risk of Secondary Cancer After CAR T-Cell Therapy

In a single-center study reported in The New England Journal of Medicine, Hamilton et al found that second tumors had occurred in 25 of 724 patients during...

Lymphoma
Immunotherapy

Phase I Study in NHL: Use of ‘Armored’ CAR T Cells May Be Feasible After Standard CAR T-Cell Failure

A novel “armored” chimeric antigen receptor (CAR) T cell appears to be feasible for retreatment of patients with non-Hodgkin lymphoma (NHL) who fail to respond...

Gastroesophageal Cancer

Esophageal Cancer: Neoadjuvant Triplet or Doublet Chemotherapy, With or Without Radiotherapy

As reported in The Lancet by Ken Kato, MD, and colleagues, the Japanese phase III JCOG1109 NExT trial showed that neoadjuvant triplet chemotherapy was associated...


Advertisement
Breast Cancer

Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy in Premenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer

As reported by Yen-Shen Lu, MD, PhD, and colleagues in the Journal of Clinical Oncology, final results of the phase II RIGHT Choice study indicate that ribociclib...

Bladder Cancer

Pembrolizumab in High-Risk Non–Muscle-Invasive Bladder Cancer

As reported in The Lancet Oncology by Andrea Necchi, MD, and colleagues, findings in cohort B of the phase II KEYNOTE-057 study indicated that pembrolizumab...

Advertisement
Advertisement





More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Guideline Update Seeks to Aid Clinicians in the Selection of Systemic Treatments for Advanced Hepatocellular Carcinoma

An ASCO guideline update offers new recommendations on systemic treatment for advanced hepatocellular carcinoma (HCC), based on promising findings from several recent randomized controlled trials as well as the approval of new first- and second-line immunotherapy combinations.1 John D. Gordan, ...

Advertisement

Oral SERDs Poised to Impact Treatment of Hormone Receptor–Positive Breast Cancer

Suppression of the estrogen receptor has proven to be an effective treatment for hormone receptor–positive breast cancer, but standard endocrine therapies have liabilities that are not limited to their pharmacokinetics or toxicity profiles, which allow for ligand-independent estrogen receptor...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Palliative Care

In Celebration of a Remarkable Life and Career in Oncology

Jamie H. Von Roenn, MD, FASCO When Jamie H. Von Roenn, MD, FASCO, graduated from high school in 1970 and enrolled at the University of Illinois in Champaign, she was determined to seek a career in special education, because she wanted to “help people through difficult situations.” Although...

Issues in Oncology

FDA’s Oncology Center of Excellence Launches Project 5 in 5, a Crowdsourcing Initiative

OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team,...

Metastatic Colorectal Cancer: Addition of Atezolizumab to First-Line FOLFOXIRI/Bevacizumab

As reported in the Journal of Clinical Oncology by Antoniotti et al, 4-year follow-up of the Italian phase II ATEZOTRIBE trial showed a numeric benefit in overall survival with the addition of atezolizumab to first-line FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) and...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Colorectal Cancer

I Am Living With Recurring Stage IV Colorectal Cancer

Despite urgings from my primary care physician to get a colonoscopy screening after I turned 50, I resisted. As a health-care provider, and someone who is tuned into changes in my body, I thought I would instinctively know if I had a serious illness. I was wrong. Even after finally relenting to at...

Advertisement

Celecoxib May Benefit a Subset of Patients With PIK3CA Mutations

Researchers have found that administering the anti-inflammatory drug celecoxib after surgery may improve disease-free survival in a subset of patients with PIK3CA-mutated stage III colorectal cancer, according to a study published by Nowak et al in the Journal of Clinical Oncology. The findings...

ASCO Post X Feed
Social Media Hub by Everwall